Table of Contents Author Guidelines Submit a Manuscript
International Journal of Analytical Chemistry
Volume 2017, Article ID 2341876, 6 pages
https://doi.org/10.1155/2017/2341876
Research Article

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma

1Division of Pharmacy, National Cancer Center Hospital East, Chiba, Japan
2Division of Functional Imaging, National Cancer Center, Chiba, Japan
3Division of Head and Neck Oncology, National Cancer Center Hospital East, Chiba, Japan
4Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Hyogo, Japan

Correspondence should be addressed to Tomoko Ogawa-Morita; pj.og.ccn.tsae@awagoot

Received 28 March 2017; Accepted 16 May 2017; Published 7 June 2017

Academic Editor: Günther K. Bonn

Copyright © 2017 Tomoko Ogawa-Morita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Matsui, Y. Funahashi, T. Uenaka, T. Watanabe, A. Tsuruoka, and M. Asada, “Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase,” Clinical Cancer Research, vol. 14, no. 17, pp. 5459–5465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Matsui, Y. Yamamoto, Y. Funahashi et al., “E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition,” International Journal of Cancer, vol. 122, no. 3, pp. 664–671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. I. Sherman, B. Jarzab, M. E. Cabanillas et al., “A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC),” Journal of Clinical Oncology, vol. 29, supplement 5503, 2011. View at Publisher · View at Google Scholar
  4. M. Schlumberger, M. Tahara, L. J. Wirth et al., “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,” The New England Journal of Medicine, vol. 372, no. 7, pp. 621–630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. A. C. Dubbelman, H. Rosing, B. Thijssen et al., “Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 887-888, pp. 25–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Mano and K. Kusano, “A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 114, pp. 82–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. MHLW, “Guideline on Bioanalytical Method Validation in Pharmaceutical Development in Japan,” 2013.
  8. N. Varsamidakis, M. Kanakis, T. Thomas, M. Kati, and E. Kostopanagiotou, “Dysphagia as the presenting symptom of thyroid cancer,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 9, pp. 511–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Almeida, A. E. Sanabria, E. N. P. Lima, and L. P. Kowalski, “Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer,” Head Neck, vol. 33, no. 5, pp. 686–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Raber-Durlacher, M. T. Brennan, I. M. Verdonck-De Leeuw et al., “Swallowing dysfunction in cancer patients,” Supportive Care in Cancer, vol. 20, no. 3, pp. 433–443, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. O. Morita, A. Yamaguchi, S. Kimura et al., “Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration,” Journal of Oncology Pharmacy Practice, vol. 22, no. 4, pp. 579–583, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Yano, T. Takezawa, T. Mochizuki et al., “Stability of drugs when prepared for tube administration by simple suspension method,” Japanese Journal of Pharmaceutical Health Care and Sciences, vol. 32, no. 11, pp. 1094–1099, 2006. View at Publisher · View at Google Scholar
  13. E. Miyamoto, A. Kawaguchi, N. Hamaguchi et al., “Evaluation of generic oral products using dissolution tests and the simple suspension method,” Japanese Journal of Pharmaceutical Health Care and Sciences, vol. 33, no. 11, pp. 942–947, 2007. View at Publisher · View at Google Scholar
  14. N. Suryani, E. Sugiyama, N. Kurata, and H. Sato, “Stability of ester prodrugs with magnesium oxide using the simple suspension method,” Japanese Journal of Pharmaceutical Health Care and Sciences, vol. 39, no. 6, pp. 375–380, 2013. View at Publisher · View at Google Scholar
  15. M. Murakami, Y. Ikemoto, N. Toya et al., “Examination regarding the simple suspension method using oral anticancer drugs,” Journal of the Pharmaceutical Society, vol. 35, no. 1, pp. 34–37, 2016. View at Google Scholar